DE2640431A1 - Modifiziertes menschliches wachstumshormon und verfahren zu seiner herstellung - Google Patents
Modifiziertes menschliches wachstumshormon und verfahren zu seiner herstellungInfo
- Publication number
- DE2640431A1 DE2640431A1 DE19762640431 DE2640431A DE2640431A1 DE 2640431 A1 DE2640431 A1 DE 2640431A1 DE 19762640431 DE19762640431 DE 19762640431 DE 2640431 A DE2640431 A DE 2640431A DE 2640431 A1 DE2640431 A1 DE 2640431A1
- Authority
- DE
- Germany
- Prior art keywords
- acid residues
- amino acid
- residue
- hgh
- subtilisin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 25
- 102000002265 Human Growth Hormone Human genes 0.000 title claims description 16
- 108010000521 Human Growth Hormone Proteins 0.000 title claims description 16
- 239000000854 Human Growth Hormone Substances 0.000 title claims description 16
- 238000004519 manufacturing process Methods 0.000 title description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 17
- 108091005804 Peptidases Proteins 0.000 claims description 12
- 102000035195 Peptidases Human genes 0.000 claims description 12
- 235000019833 protease Nutrition 0.000 claims description 12
- 108090000787 Subtilisin Proteins 0.000 claims description 11
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 230000004071 biological effect Effects 0.000 claims description 3
- 108010056079 Subtilisins Proteins 0.000 claims description 2
- 102000005158 Subtilisins Human genes 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 108010088842 Fibrinolysin Proteins 0.000 description 6
- 229940001501 fibrinolysin Drugs 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000012510 peptide mapping method Methods 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61092575A | 1975-09-08 | 1975-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2640431A1 true DE2640431A1 (de) | 1977-03-17 |
Family
ID=24446955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19762640431 Pending DE2640431A1 (de) | 1975-09-08 | 1976-09-08 | Modifiziertes menschliches wachstumshormon und verfahren zu seiner herstellung |
Country Status (4)
| Country | Link |
|---|---|
| DE (1) | DE2640431A1 (it) |
| GB (1) | GB1529097A (it) |
| IT (1) | IT1066215B (it) |
| SE (1) | SE7609861L (it) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0356107A2 (en) * | 1988-08-19 | 1990-02-28 | Eli Lilly And Company | Proteins having growth hormone anabolic properties with reduced effect on carbohydrate metabolism |
-
1976
- 1976-08-30 IT IT51086/76A patent/IT1066215B/it active
- 1976-09-06 GB GB36893/76A patent/GB1529097A/en not_active Expired
- 1976-09-07 SE SE7609861A patent/SE7609861L/xx unknown
- 1976-09-08 DE DE19762640431 patent/DE2640431A1/de active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0356107A2 (en) * | 1988-08-19 | 1990-02-28 | Eli Lilly And Company | Proteins having growth hormone anabolic properties with reduced effect on carbohydrate metabolism |
| EP0356107A3 (en) * | 1988-08-19 | 1991-08-14 | Eli Lilly And Company | Proteins having growth hormone anabolic properties with reduced effect on carbohydrate metabolism |
Also Published As
| Publication number | Publication date |
|---|---|
| IT1066215B (it) | 1985-03-04 |
| SE7609861L (sv) | 1977-03-09 |
| GB1529097A (en) | 1978-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3686654T2 (de) | Verfahren zur isolierung rekombinanter polypeptide in biologisch aktiver form. | |
| EP0297457B1 (de) | Kosmetisches Mittel | |
| EP1003786B1 (de) | Peptid mit radioprotektiver wirkung | |
| DE3588249T2 (de) | Methode zur Herstellung von menschlichen Wachstumshormonen | |
| DE3884776T2 (de) | Durch "site-directed" Mutagenese modifzierte Glukoprotein-Hormone und Verfahren zu deren Verwendung. | |
| EP0046979A1 (de) | Analoga des Insulins | |
| DE3230151A1 (de) | Neues polypeptid mit wirkung auf das immunsystem, verfahren zu seiner isolierung und reinigung, seine verwendung, dieses enthaltende mittel sowie seine spaltprodukte, deren verwendung und diese enthaltende mittel | |
| Landmann et al. | Irreversible synthetische inhibitoren der Urokinase | |
| DE3806423C2 (de) | Verfahren zur Herstellung von Pectin | |
| DE69911024T2 (de) | Methoden zur herstellung von rekombinanten peptiden mit einer geringen menge von trisulfiden | |
| Derby | The effect of prolactin and thyroxine on tail resorption in R. pipiens: in vivo and in vitro | |
| DE69124561T2 (de) | Methode zur reinigung von polypeptiden | |
| CH683317A5 (de) | Verfahren zur Herstellung eines Haarnährmittels. | |
| DE2640431A1 (de) | Modifiziertes menschliches wachstumshormon und verfahren zu seiner herstellung | |
| DE1940130C2 (de) | Verfahren zur Reinigung von Insulin, nach diesem Verfahren gereinigtes Insulin und dessen Verwendung | |
| DE69220939T2 (de) | Gegengift immunsera | |
| DE69720303T2 (de) | Mittel zur Inhibierung von Eingeweidefettakkumulation | |
| DE3243358A1 (de) | Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose | |
| EP0194600A2 (de) | Hemmung humaner Speichel- und Pankreasamylase durch monoklonale Antikörper | |
| WO1992010515A1 (de) | Derivate des humanen parathormon-fragments (1-37) in der form des amids oder ethylamids als aktiven wirkstoff | |
| DE69012958T2 (de) | Fibrinolytisches Protein und Herstellungsweise dafür. | |
| DE2006514C3 (de) | Ein Verfahren zur Herstellung von proteolytischen enzymatischen Produkten, die in vivo dem Schleim des Darmkanals, dem Bronchialschleim und dem Zervixschleim die optimale Viskosität verleihen und deren Verwendung als Zusatz in Nahrungs- und Futtermitteln | |
| DE2447050A1 (de) | Verfahren zur gewinnung von proteasenhemmstoff | |
| DE69202136T2 (de) | Neuartiges calcitonin, und seine herstellung und verwendung. | |
| EP0133308B1 (de) | Appetitregulierender Wirkstoff und Verfahren zur Herstellung desselben |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHJ | Non-payment of the annual fee |